vs

Side-by-side financial comparison of Brookfield Infrastructure Corp (BIPC) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

Brookfield Infrastructure Corp is the larger business by last-quarter revenue ($866.0M vs $805.0M, roughly 1.1× West Pharmaceutical Services). West Pharmaceutical Services runs the higher net margin — 16.4% vs -35.7%, a 52.1% gap on every dollar of revenue. On growth, West Pharmaceutical Services posted the faster year-over-year revenue change (7.5% vs -4.6%).

Brookfield Infrastructure Partners L.P. is a publicly traded limited partnership with corporate headquarters in Toronto, Canada, that engages in the acquisition and management of infrastructure assets on a global basis.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

BIPC vs WST — Head-to-Head

Bigger by revenue
BIPC
BIPC
1.1× larger
BIPC
$866.0M
$805.0M
WST
Growing faster (revenue YoY)
WST
WST
+12.1% gap
WST
7.5%
-4.6%
BIPC
Higher net margin
WST
WST
52.1% more per $
WST
16.4%
-35.7%
BIPC

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
BIPC
BIPC
WST
WST
Revenue
$866.0M
$805.0M
Net Profit
$-309.0M
$132.1M
Gross Margin
65.0%
37.8%
Operating Margin
62.7%
19.5%
Net Margin
-35.7%
16.4%
Revenue YoY
-4.6%
7.5%
Net Profit YoY
-148.1%
1.5%
EPS (diluted)
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIPC
BIPC
WST
WST
Q4 25
$805.0M
Q3 25
$804.6M
Q2 25
$866.0M
$766.5M
Q1 25
$698.0M
Q4 24
$748.8M
Q3 24
$746.9M
Q2 24
$908.0M
$702.1M
Q1 24
$695.4M
Net Profit
BIPC
BIPC
WST
WST
Q4 25
$132.1M
Q3 25
$140.0M
Q2 25
$-309.0M
$131.8M
Q1 25
$89.8M
Q4 24
$130.1M
Q3 24
$136.0M
Q2 24
$643.0M
$111.3M
Q1 24
$115.3M
Gross Margin
BIPC
BIPC
WST
WST
Q4 25
37.8%
Q3 25
36.6%
Q2 25
65.0%
35.7%
Q1 25
33.2%
Q4 24
36.5%
Q3 24
35.4%
Q2 24
63.8%
32.8%
Q1 24
33.1%
Operating Margin
BIPC
BIPC
WST
WST
Q4 25
19.5%
Q3 25
20.8%
Q2 25
62.7%
20.1%
Q1 25
15.3%
Q4 24
21.3%
Q3 24
21.6%
Q2 24
61.9%
18.0%
Q1 24
17.7%
Net Margin
BIPC
BIPC
WST
WST
Q4 25
16.4%
Q3 25
17.4%
Q2 25
-35.7%
17.2%
Q1 25
12.9%
Q4 24
17.4%
Q3 24
18.2%
Q2 24
70.8%
15.9%
Q1 24
16.6%
EPS (diluted)
BIPC
BIPC
WST
WST
Q4 25
$1.82
Q3 25
$1.92
Q2 25
$1.82
Q1 25
$1.23
Q4 24
$1.78
Q3 24
$1.85
Q2 24
$1.51
Q1 24
$1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIPC
BIPC
WST
WST
Cash + ST InvestmentsLiquidity on hand
$1.2B
$791.3M
Total DebtLower is stronger
$202.8M
Stockholders' EquityBook value
$2.2B
$3.2B
Total Assets
$23.9B
$4.3B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIPC
BIPC
WST
WST
Q4 25
$791.3M
Q3 25
$628.5M
Q2 25
$1.2B
$509.7M
Q1 25
$404.2M
Q4 24
$484.6M
Q3 24
$490.9M
Q2 24
$466.0M
$446.2M
Q1 24
$601.8M
Total Debt
BIPC
BIPC
WST
WST
Q4 25
$202.8M
Q3 25
$202.7M
Q2 25
$202.6M
Q1 25
$202.6M
Q4 24
$202.6M
Q3 24
$202.6M
Q2 24
$205.8M
Q1 24
$206.2M
Stockholders' Equity
BIPC
BIPC
WST
WST
Q4 25
$3.2B
Q3 25
$3.1B
Q2 25
$2.2B
$2.9B
Q1 25
$2.7B
Q4 24
$2.7B
Q3 24
$2.8B
Q2 24
$3.5B
$2.6B
Q1 24
$2.7B
Total Assets
BIPC
BIPC
WST
WST
Q4 25
$4.3B
Q3 25
$4.1B
Q2 25
$23.9B
$4.0B
Q1 25
$3.6B
Q4 24
$3.6B
Q3 24
$3.7B
Q2 24
$23.7B
$3.5B
Q1 24
$3.6B
Debt / Equity
BIPC
BIPC
WST
WST
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.08×
Q4 24
0.08×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIPC
BIPC
WST
WST
Operating Cash FlowLast quarter
$478.0M
$251.1M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
21.7%
Capex IntensityCapex / Revenue
9.5%
Cash ConversionOCF / Net Profit
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIPC
BIPC
WST
WST
Q4 25
$251.1M
Q3 25
$197.2M
Q2 25
$478.0M
$177.1M
Q1 25
$129.4M
Q4 24
$190.1M
Q3 24
$180.1M
Q2 24
$511.0M
$165.0M
Q1 24
$118.2M
Free Cash Flow
BIPC
BIPC
WST
WST
Q4 25
$175.0M
Q3 25
$133.9M
Q2 25
$101.9M
Q1 25
$58.1M
Q4 24
$85.2M
Q3 24
$98.8M
Q2 24
$64.8M
Q1 24
$27.6M
FCF Margin
BIPC
BIPC
WST
WST
Q4 25
21.7%
Q3 25
16.6%
Q2 25
13.3%
Q1 25
8.3%
Q4 24
11.4%
Q3 24
13.2%
Q2 24
9.2%
Q1 24
4.0%
Capex Intensity
BIPC
BIPC
WST
WST
Q4 25
9.5%
Q3 25
7.9%
Q2 25
9.8%
Q1 25
10.2%
Q4 24
14.0%
Q3 24
10.9%
Q2 24
14.3%
Q1 24
13.0%
Cash Conversion
BIPC
BIPC
WST
WST
Q4 25
1.90×
Q3 25
1.41×
Q2 25
1.34×
Q1 25
1.44×
Q4 24
1.46×
Q3 24
1.32×
Q2 24
0.79×
1.48×
Q1 24
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIPC
BIPC

Segment breakdown not available.

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons